Enterprise Value

697M

Cash

250.9M

Avg Qtr Burn

-83.77M

Short % of Float

18.46%

Insider Ownership

0.33%

Institutional Own.

91.41%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Lifileucel Details
Melanoma, Cancer

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Iovance TIL (LN-145) Details
Non-small cell lung carcinoma, Cancer

Phase 2

Data readout

Phase 2

Update

Lifileucel Details
Cancer, Cervical cancer

Phase 2

Update

IOV-4001 Details
Non-small cell lung carcinoma, Cancer, Melanoma

Phase 1/2

Update